100 related articles for article (PubMed ID: 14987837)
1. Anthranilic acid based CCK1 antagonists: the 2-indole moiety may represent a "needle" according to the recent homonymous concept.
Varnavas A; Lassiani L; Valenta V; Berti F; Tontini A; Mennuni L; Makovec F
Eur J Med Chem; 2004 Jan; 39(1):85-97. PubMed ID: 14987837
[TBL] [Abstract][Full Text] [Related]
2. Anthranilic acid based CCK1 receptor antagonists: preliminary investigation on their second "touch point".
Varnavas A; Lassiani L; Valenta V; Mennuni L; Makovec F; Hadjipavlou-Litina D
Eur J Med Chem; 2005 Jun; 40(6):563-81. PubMed ID: 15922840
[TBL] [Abstract][Full Text] [Related]
3. New anthranilic acid based antagonists with high affinity and selectivity for the human cholecystokinin receptor 1 (hCCK1-R).
Pavan MV; Lassiani L; Berti F; Stefancich G; Ciogli A; Gasparrini F; Mennuni L; Ferrari F; Escrieut C; Marco E; Makovec F; Fourmy D; Varnavas A
J Med Chem; 2011 Aug; 54(16):5769-85. PubMed ID: 21728335
[TBL] [Abstract][Full Text] [Related]
4. Anthranilic acid derivatives: a new class of non-peptide CCK1 receptor antagonists.
Varnavas A; Lassiani L; Valenta V; Berti F; Mennuni L; Makovec F
Bioorg Med Chem; 2003 Mar; 11(5):741-51. PubMed ID: 12538004
[TBL] [Abstract][Full Text] [Related]
5. Identification and optimization of anthranilic sulfonamides as novel, selective cholecystokinin-2 receptor antagonists.
Allison BD; Phuong VK; McAtee LC; Rosen M; Morton M; Prendergast C; Barrett T; Lagaud G; Freedman J; Li L; Wu X; Venkatesan H; Pippel M; Woods C; Rizzolio MC; Hack M; Hoey K; Deng X; King C; Shankley NP; Rabinowitz MH
J Med Chem; 2006 Oct; 49(21):6371-90. PubMed ID: 17034143
[TBL] [Abstract][Full Text] [Related]
6. Anthranilic acid based CCK1 receptor antagonists and CCK-8 have a common step in their "receptor desmodynamic processes".
De Luca S; Saviano M; Lassiani L; Yannakopoulou K; Stefanidou P; Aloj L; Morelli G; Varnavas A
J Med Chem; 2006 Apr; 49(8):2456-62. PubMed ID: 16610788
[TBL] [Abstract][Full Text] [Related]
7. N-terminal anthranoyl-phenylalanine derivatives as CCK1 receptor antagonists: the final approach.
Varnavas A; Lassiani L; Valenta V; Ciogli A; Gasparrini F; Mennuni L; Makovec F
Med Chem; 2005 Sep; 1(5):501-17. PubMed ID: 16787335
[TBL] [Abstract][Full Text] [Related]
8. Anthranilic acid based CCK1 receptor antagonists: blocking the receptor with the same 'words' of the endogenous ligand.
Lassiani L; Pavan MV; Berti F; Kokotos G; Markidis T; Mennuni L; Makovec F; Varnavas A
Bioorg Med Chem; 2009 Mar; 17(6):2336-50. PubMed ID: 19261479
[TBL] [Abstract][Full Text] [Related]
9. Anthranilic sulfonamide CCK1/CCK2 dual receptor antagonists I: discovery of CCKR1 selectivity in a previously CCKR2-selective lead series.
Pippel M; Allison BD; Phuong VK; Li L; Morton MF; Prendergast C; Wu X; Shankley NP; Rabinowitz MH
Bioorg Med Chem Lett; 2009 Nov; 19(22):6373-5. PubMed ID: 19811913
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and solid-phase purification of anthranilic sulfonamides as CCK-2 ligands.
Woods CR; Hack MD; Allison BD; Phuong VK; Rosen MD; Morton MF; Prendergast CE; Barrett TD; Shankley NP; Rabinowitz MH
Bioorg Med Chem Lett; 2007 Dec; 17(24):6905-9. PubMed ID: 18029172
[TBL] [Abstract][Full Text] [Related]
11. 3-[5-(3,4-Dichloro-phenyl)-1-(4-methoxy-phenyl)-1H-pyrazol-3-yl]-2-m-tolyl-propionate (JNJ-17156516), a novel, potent, and selective cholecystokinin 1 receptor antagonist: in vitro and in vivo pharmacological comparison with dexloxiglumide.
Morton MF; Barrett TD; Yan W; Freedman JM; Lagaud G; Prendergast CE; Moreno V; Pyati J; Figueroa K; Li L; Wu X; Rizzolio M; Breitenbucher JG; McClure K; Shankley NP
J Pharmacol Exp Ther; 2007 Nov; 323(2):562-9. PubMed ID: 17684117
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and evaluation of N-(3-oxo-2,3-dihydro-1H-pyrazol-4-yl)-1H-indole-carboxamides as cholecystokinin antagonists.
Lattmann E; Singh H; Boonprakob Y; Lattmann P; Sattayasai J
J Pharm Pharmacol; 2006 Mar; 58(3):393-401. PubMed ID: 16536908
[TBL] [Abstract][Full Text] [Related]
13. Development of 3-substituted-1H-indole derivatives as NR2B/NMDA receptor antagonists.
Gitto R; De Luca L; Ferro S; Citraro R; De Sarro G; Costa L; Ciranna L; Chimirri A
Bioorg Med Chem; 2009 Feb; 17(4):1640-7. PubMed ID: 19157884
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and receptor binding affinity of cholecystokinin receptor ligands: 2-and 1-indolyl derivatives of PD134308.
Araldi G; Donati D; Oliosi B; Ursini A; van Amsterdam F; Natalini B; Pellicciari R; Tarzia G
Farmaco; 1996 Jul; 51(7):471-6. PubMed ID: 8765669
[TBL] [Abstract][Full Text] [Related]
15. 5-(tryptophylamino)-1,3-dioxoperhydropyrido[1,2-c]pyrimidine-based cholecystokinin receptor antagonists: reversal of CCK1 receptor subtype selectivity toward CCK2 receptors.
Muñoz-Ruiz P; García-López MT; Cenarruzabeitia E; Del Río J; Dufresne M; Foucaud M; Fourmy D; Herranz R
J Med Chem; 2004 Oct; 47(21):5318-29. PubMed ID: 15456276
[TBL] [Abstract][Full Text] [Related]
16. CoMFA, synthesis, and pharmacological evaluation of (E)-3-(2-carboxy-2-arylvinyl)-4,6-dichloro-1H-indole-2-carboxylic acids: 3-[2-(3-aminophenyl)-2-carboxyvinyl]-4,6-dichloro-1H-indole-2-carboxylic acid, a potent selective glycine-site NMDA receptor antagonist.
Baron BM; Cregge RJ; Farr RA; Friedrich D; Gross RS; Harrison BL; Janowick DA; Matthews D; McCloskey TC; Meikrantz S; Nyce PL; Vaz R; Metz WA
J Med Chem; 2005 Feb; 48(4):995-1018. PubMed ID: 15715469
[TBL] [Abstract][Full Text] [Related]
17. (S)-N-{3-[1-cyclopropyl-1-(2,4-difluoro-phenyl)-ethyl]-1H-indol-7-yl}-methanesulfonamide: a potent, nonsteroidal, functional antagonist of the mineralocorticoid receptor.
Bell MG; Gernert DL; Grese TA; Belvo MD; Borromeo PS; Kelley SA; Kennedy JH; Kolis SP; Lander PA; Richey R; Sharp VS; Stephenson GA; Williams JD; Yu H; Zimmerman KM; Steinberg MI; Jadhav PK
J Med Chem; 2007 Dec; 50(26):6443-5. PubMed ID: 18038968
[TBL] [Abstract][Full Text] [Related]
18. Activation of cholecystokinin (CCK 1) and serotonin (5-HT 3) receptors increases the discharge of pancreatic vagal afferents.
Mussa BM; Sartor DM; Verberne AJ
Eur J Pharmacol; 2008 Dec; 601(1-3):198-206. PubMed ID: 19026634
[TBL] [Abstract][Full Text] [Related]
19. Novel, achiral 1,3,4-benzotriazepine analogues of 1,4-benzodiazepine-based CCK(2) antagonists that display high selectivity over CCK(1) receptors.
McDonald IM; Austin C; Buck IM; Dunstone DJ; Griffin E; Harper EA; Hull RA; Kalindjian SB; Linney ID; Low CM; Pether MJ; Spencer J; Wright PT; Adatia T; Bashall A
J Med Chem; 2006 Apr; 49(7):2253-61. PubMed ID: 16570921
[TBL] [Abstract][Full Text] [Related]
20. Conformationally constrained CCK4 analogues incorporating IBTM and BTD beta-turn mimetics.
Martín-Martínez M; De la Figuera N; Latorre M; García-López MT; Cenarruzabeitia E; Del Río J; González-Muñiz R
J Med Chem; 2005 Dec; 48(24):7667-74. PubMed ID: 16302807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
